TMO - Thermo Fisher Scientific Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Waltham,
United States
Type: Equity
TMO price evolution
TMO
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7073 | $5499 | $8077 | |
| Short term investments | $1750 | $1751 | ||
| Net receivables | $8255 | $7943 | $7931 | $8221 |
| Inventory | $5430 | $5198 | $5133 | $5088 |
| Total current assets | $23783 | $25476 | $23640 | $24589 |
| Long term investments | ||||
| Property, plant & equipment | $9412 | $9282 | $9324 | $9448 |
| Goodwill & intangible assets | $59362 | $59891 | $60690 | |
| Total noncurrent assets | $73020 | $73455 | $74137 | |
| Total investments | $1750 | $1751 | ||
| Total assets | $100364 | $98496 | $97095 | $98726 |
| Current liabilities | ||||
| Accounts payable | $2606 | $2547 | $2555 | $2872 |
| Deferred revenue | $2591 | $2632 | $2689 | |
| Short long term debt | $5121 | $4451 | $3609 | |
| Total current liabilities | $14601 | $14772 | $13937 | $14012 |
| Long term debt | $31197 | $30284 | $31157 | $31308 |
| Total noncurrent liabilities | $36305 | $37654 | $37990 | |
| Total debt | $35405 | $35608 | $34917 | |
| Total liabilities | $51392 | $51077 | $51591 | $52002 |
| Shareholders' equity | ||||
| Retained earnings | $51421 | $49940 | $48542 | $47364 |
| Other shareholder equity | $48972 | -$2413 | -$2764 | $46724 |
| Total shareholder equity | $47432 | $45516 | $46735 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8077 | $8524 | $4477 | $10325 |
| Short term investments | ||||
| Net receivables | $8221 | $8274 | $7977 | $5741 |
| Inventory | $5088 | $5634 | $5051 | $4029 |
| Total current assets | $24589 | $25365 | $20113 | $21957 |
| Long term investments | $53 | |||
| Property, plant & equipment | $9448 | $9280 | $8333 | $5912 |
| Goodwill & intangible assets | $60690 | $58638 | $62037 | $38726 |
| Total noncurrent assets | $74137 | $71925 | $75010 | $47095 |
| Total investments | ||||
| Total assets | $98726 | $97290 | $95123 | $69052 |
| Current liabilities | ||||
| Accounts payable | $2872 | $3381 | $2867 | $2175 |
| Deferred revenue | $2689 | $2601 | $2655 | $1271 |
| Short long term debt | $3609 | $5579 | $2537 | $2628 |
| Total current liabilities | $14012 | $17114 | $13436 | $10304 |
| Long term debt | $31308 | $28909 | $32333 | $19107 |
| Total noncurrent liabilities | $37990 | $36112 | $40832 | $24241 |
| Total debt | $34917 | $34488 | $34870 | $21735 |
| Total liabilities | $52002 | $53258 | $54268 | $34545 |
| Shareholders' equity | ||||
| Retained earnings | $47364 | $41910 | $35431 | $28116 |
| Other shareholder equity | $46724 | $44032 | -$2329 | -$2807 |
| Total shareholder equity | $46735 | $43978 | $40793 | $34507 |
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10598 | $10541 | $10886 | |
| Cost of revenue | $6194 | |||
| Gross Profit | $4418 | $4347 | $4496 | |
| Operating activities | ||||
| Research & development | $339 | |||
| Selling, general & administrative | $2111 | |||
| Total operating expenses | $2535 | $2527 | $2562 | |
| Operating income | $1820 | |||
| Income from continuing operations | ||||
| EBIT | $2030 | |||
| Income tax expense | $99 | $128 | $133 | |
| Interest expense | -$79 | $354 | -$81 | |
| Net income | ||||
| Net income | $1630 | $1548 | $1630 | |
| Income (for common shares) | $1548 | |||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $42857 | $44915 | $32218 | |
| Cost of revenue | $25944 | $16214 | ||
| Gross Profit | $17562 | $18971 | $16004 | |
| Operating activities | ||||
| Research & development | $1471 | $1181 | ||
| Selling, general & administrative | $8993 | $6930 | ||
| Total operating expenses | $10244 | $10578 | $8210 | |
| Operating income | $8393 | $7794 | ||
| Income from continuing operations | ||||
| EBIT | $8379 | $7778 | ||
| Income tax expense | $284 | $703 | $850 | |
| Interest expense | -$496 | $726 | $553 | |
| Net income | ||||
| Net income | $5995 | $6950 | $6375 | |
| Income (for common shares) | $6950 | $6375 | ||
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $1548 | $1328 | ||
| Operating activities | ||||
| Depreciation | $791 | $836 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $84 | $70 | ||
| Total cash flows from operations | $1960 | $1251 | ||
| Investing activities | ||||
| Capital expenditures | -$285 | -$343 | ||
| Investments | -$20 | -$1758 | ||
| Total cash flows from investing | -$5861 | -$253 | -$2030 | -$5142 |
| Financing activities | ||||
| Dividends paid | -$434 | -$149 | -$135 | -$523 |
| Sale and purchase of stock | -$3000 | |||
| Net borrowings | -$1 | $1205 | ||
| Total cash flows from financing | -$3126 | -$115 | -$1821 | -$3622 |
| Effect of exchange rate | $182 | -$15 | $22 | -$82 |
| Change in cash and equivalents | -$3427 | $1578 | -$2578 | -$440 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $6950 | $7725 | $6375 | |
| Operating activities | ||||
| Depreciation | $3381 | $2592 | $2325 | |
| Business acquisitions & disposals | -$39 | -$19395 | -$38 | |
| Stock-based compensation | $307 | $230 | $196 | |
| Total cash flows from operations | $9154 | $9312 | $8289 | |
| Investing activities | ||||
| Capital expenditures | -$2219 | -$2503 | -$1466 | |
| Investments | ||||
| Total cash flows from investing | -$5142 | -$2159 | -$21932 | -$1510 |
| Financing activities | ||||
| Dividends paid | -$523 | -$455 | -$395 | -$337 |
| Sale and purchase of stock | -$3000 | -$1844 | -$1304 | |
| Net borrowings | $654 | $8911 | $2747 | |
| Total cash flows from financing | -$3622 | -$2810 | $6581 | $959 |
| Effect of exchange rate | -$82 | -$139 | $194 | $176 |
| Change in cash and equivalents | -$440 | $4046 | -$5845 | $7914 |
News
Fundamentals
| Market cap | $207.16B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 382.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 0.23% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.11 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.63 |
| Quick ratio | 1.26 |